Related references
Note: Only part of the references are listed.Immunotherapeutic approaches for cancer therapy: An updated review
Tohid Kazemi et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2016)
Biomarkers in Cancer Immunotherapy
Ton N. Schumacher et al.
CANCER CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Oncolytic Virus Immunotherapy for Melanoma
Neal Dharmadhikari et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Adoptive T-Cell Therapy for Cancer in the United Kingdom: A Review of Activity for the British Society of Gene and Cell Therapy Annual Meeting 2015
David Edward Gilham et al.
HUMAN GENE THERAPY (2015)
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
Douglas B. Johnson et al.
IMMUNOTHERAPY (2015)
Cancer-fighting viruses win approval
Heidi Ledford
NATURE (2015)
TRIAL WATCH Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy
Megan Cully
NATURE REVIEWS DRUG DISCOVERY (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Releasing the Brakes on Cancer Immunotherapy
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
David R. Minor et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Neuropilin 1: function and therapeutic potential in cancer
Belal Chaudhary et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Exploiting the curative potential of adoptive T-cell therapy for cancer
Christian S. Hinrichs et al.
IMMUNOLOGICAL REVIEWS (2014)
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Yannick Bulliard et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
Colin D. Weekes et al.
INVESTIGATIONAL NEW DRUGS (2014)
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma A Randomized Clinical Trial
F. Stephen Hodi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
被撤回的出版物: Targeting CD137 enhances the efficacy of cetuximab (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Oriana Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Intralesional Immunotherapy for Melanoma
Peter Hersey et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Therapeutic vaccines for cancer: an overview of clinical trials
Ignacio Melero et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
Oncolytic Viruses and Their Application to Cancer Immunotherapy
E. Antonio Chiocca et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cell Transfer Therapy for Cancer: Past, Present, and Future
Xiaoling Qian et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
David A. Schaer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Going viral with cancer immunotherapy
Brian D. Lichty et al.
NATURE REVIEWS CANCER (2014)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Dendritic cell immunotherapy
Rachel Lubong Sabado et al.
RENAISSANCE OF CANCER IMMUNOTHERAPY (2013)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Adoptive T-Cell Therapy for Cancer: Boutique Therapy or Treatment Modality?
Cassian Yee
CLINICAL CANCER RESEARCH (2013)
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Karolina Palucka et al.
IMMUNITY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity
Christine Pasero et al.
IMMUNOLOGY LETTERS (2013)
Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model
Alexandra Sevko et al.
JOURNAL OF IMMUNOLOGY (2013)
PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice
Mulu Z. Tesfay et al.
JOURNAL OF VIROLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1
David C. Gaston et al.
PLOS ONE (2013)
Generation of more effective cancer vaccines
Daniela Fenoglio et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Cancer vaccines Looking to the future
Kavitha Yaddanapudi et al.
ONCOIMMUNOLOGY (2013)
Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity
K. B. Stephenson et al.
CANCER GENE THERAPY (2012)
CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
Julien Fourcade et al.
CANCER RESEARCH (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Dung T. Le et al.
CANCER RESEARCH (2012)
Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
Inge Verbrugge et al.
CANCER RESEARCH (2012)
Modulation of GITR for cancer immunotherapy
David A. Schaer et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy
Christine Pasero et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Immunotherapy of Cancer with 4-1BB
Dass S. Vinay et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oncolytic Effects of a Novel Influenza A Virus Expressing Interleukin-15 from the NS Reading Frame
Marijke van Rikxoort et al.
PLOS ONE (2012)
Cancer immunotherapy via dendritic cells
Karolina Palucka et al.
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
The CD4-like molecule LAG-3, biology and therapeutic applications
Sophie Sierro et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα
I-K Choi et al.
GENE THERAPY (2011)
Science gone translational: the OX40 agonist story
Andrew D. Weinberg et al.
IMMUNOLOGICAL REVIEWS (2011)
Cancer Immunotherapy Comes of Age
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemoimmunotherapy
Ioannis Alagkiozidis et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Michael A. Curran et al.
PLOS ONE (2011)
Neuropilins: A New Target for Cancer Therapy
Camille Grandclement et al.
Cancers (2011)
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Padmanee Sharma et al.
NATURE REVIEWS CANCER (2011)
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
Howard L. Kaufman et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Federica Moschella et al.
THYMOSINS IN HEALTH AND DISEASE (2010)
Adoptive Cell Therapy Genetic Modification to Redirect Effector Cell Specificity
Richard A. Morgan et al.
CANCER JOURNAL (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
Begona Comin-Anduix et al.
CLINICAL CANCER RESEARCH (2010)
Dendritic cells in cancer immunotherapy
Gerold Schuler
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
Howard L. Kaufman et al.
FUTURE ONCOLOGY (2010)
Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus
Feorillo Galivo et al.
HUMAN GENE THERAPY (2010)
BTLA mediates inhibition of human tumor-specific CD8(+) T cells that can be partially reversed by vaccination
Laurent Derre et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
Kazuyoshi Takeda et al.
JOURNAL OF IMMUNOLOGY (2010)
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
Chrystelle Brignone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL
Jing-Hua Huang et al.
MOLECULAR THERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Paolo A. Ascierto et al.
SEMINARS IN ONCOLOGY (2010)
Signaling Through OX40 Enhances Antitumor Immunity
Shawn M. Jensen et al.
SEMINARS IN ONCOLOGY (2010)
The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease
Timothy R. Hercus et al.
BLOOD (2009)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand
Hong Sung Kim et al.
CANCER RESEARCH (2009)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
Chrystelle Brignone et al.
CLINICAL CANCER RESEARCH (2009)
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation
Guifang Cai et al.
IMMUNOLOGICAL REVIEWS (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Papillomaviruses in the causation of human cancers - a brief historical account
Harald zur Hausen
VIROLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Cancer chemotherapy:: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
Cedric Menard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Epitope landscape in breast and colorectal cancer
Neil H. Segal et al.
CANCER RESEARCH (2008)
Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells
Jochen Greiner et al.
CLINICAL CANCER RESEARCH (2008)
Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor
Joanne Morrison et al.
MOLECULAR THERAPY (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy
Johan Vansteenkiste et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
J. Vansteenkiste et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms
B. G. DeRubertis et al.
CANCER GENE THERAPY (2007)
Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma
Edward J. Shin et al.
LARYNGOSCOPE (2007)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model
Young-Sook Lee et al.
CLINICAL CANCER RESEARCH (2006)
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Giulia Fulci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
S Varghese et al.
CANCER GENE THERAPY (2006)
Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system
H Fukuhara et al.
CANCER RESEARCH (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
AM Thomas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance
A Sanchez-Fueyo et al.
NATURE IMMUNOLOGY (2003)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Towards patient-specific tumor antigen selection for vaccination
HG Rammensee et al.
IMMUNOLOGICAL REVIEWS (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor
M Toda et al.
MOLECULAR THERAPY (2000)
Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8+ cytotoxic T lymphocytes
C Berger et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
